| A | B | C | D | E | F | |
|---|---|---|---|---|---|---|
1 | StrongMinds cost-effectiveness analysis | Conservative estimate | Best guess estimate | Optimistic estimate | Sources | |
2 | Treatment of depression | |||||
3 | Average reduction in PHQ-9 score per participant first reported | 4.50 | StrongMinds Impact Evaluation 'Phase 2' (2015) | |||
4 | Adjustment to average reduction in PHQ-9 score per participant | 1.37 | Estimate | StrongMinds 'Follow Up Evaluations for Phase 1 & Phase 2' (2017) | ||
5 | Adjusted average reduction in PHQ-9 score per participant | 3.13 | Calculation | |||
6 | Minimum PHQ-9 score | 0 | Patient.info | |||
7 | Maximum PHQ-9 score | 27 | Patient.info | |||
8 | DALY weighting of severe major depressive disorder | 0.658 | Global Burden of Disease Study 2016 (GBD 2016) Disability Weights | |||
9 | Adjusted DALY weighting per point on PHQ-9 scale | 0.02437 | Calculation | |||
10 | DALYs averted per year per participant directly post-treatment | 0.07632 | Calculation | |||
11 | Retention rate of benefits | 70.71% | 75.04% | 79.37% | Reay et al. (2012) | StrongMinds 'Follow Up Evaluations for Phase 1 & Phase 2' (2017) |
12 | Total DALYs averted per participant | 0.22 | 0.27 | 0.33 | Calculation | |
13 | Cost per beneficiary (USD) | 101 | StrongMinds Q2 2018 Report | |||
14 | Cost per DALY averted (USD) | 454 | 377 | 304 | Calculation | |
15 | Cost per equivalent of a year of severe major depressive disorder prevented (USD) | 299 | 248 | 200 | Calculation | |